Recludix Pharma Inc. has divulged signal transducer and activator of transcription 3 (STAT3) and 6 (STAT6) inhibitors reported to be useful for the treatment of cancer and inflammation.
Tegid Therapeutics Inc. has identified proteolysis targeting chimera (PROTACs) compounds comprising cereblon (CRBN) ligands covalently bonded to a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1)-targeting moiety.
Researchers from University Hospital Basel and Universitätsklinikum Ulm presented the discovery of novel radiotheragnostic candidates targeting C-X-C chemokine receptor 4 (CXCR4), which is highly expressed in various cancers and has been linked to poor prognosis.
Researchers from Huazhong University of Science and Technology presented the discovery and preclinical evaluation of a novel peptide PET tracer targeting LAG-3, [68Ga]NOTA-XH05, being developed as a candidate for evaluating the efficacy of cancer immunotherapy.
Orionis Biosciences BV has established a multiyear collaboration with Genentech Inc., a member of the Roche Group, to discover novel small-molecule molecular glues for targets in major disease areas, including oncology and neurodegeneration.
Cyclin-dependent kinase 7 (CDK7) regulates both cell cycle and global transcription and is a validated therapeutic target in cancer. Researchers from Shanghai Hengrui Pharmaceutical Co. Ltd. reported on the discovery and preclinical evaluation of SHR-5428, a noncovalent CDK7 inhibitor.
U3-1402/patritumab-GGFG-DXd is the first HER3-targeting antibody-drug conjugate (ADC) showing clinical efficacy in non-small-cell lung cancer. However, an elevated proportion of patients with this cancer express low levels of HER3 and are nonresponsive to this ADC. In addition, novel ADCs are needed to treat other cancer types, including colorectal cancer.
Although preclinical studies of genetically engineered interleukin-18 (IL-18) historically indicated its potential in cancer treatment, interest in the cytokine languished after GSK plc shelved its IL-18 therapeutic on lack of responses in a phase II melanoma trial. But in 2020, Yale University-based professor of immunobiology Aaron Ring set about reviving IL-18 as a cancer therapeutic. He went on to engineer a decoy-resistant form of IL-18 and then founded Simcha Therapeutics Inc. to develop the drug – named ST-067.
Merck KGaA has entered deals that could bring U.K. artificial intelligence companies Benevolentai Ltd. and Exscientia plc more than $1.2 billion. Oxford, U.K.-based Exscientia and Merck will collaborate to find three small-molecule candidates in oncology, neuroinflammation and immunology. Exscientia is getting $20 million up front and could bring in $674 million in milestones payments.
Peptidream Inc. and Genentech Inc., a Roche Holding company, signed a deal worth up to $1 billion to discover and develop macrocyclic peptide-radioisotope (peptide-RI) drug conjugates. Peptidream, of Kawasaki, Japan, will use its peptide discovery platform system technology to discover, optimize and develop macrocyclic peptide candidates for use as peptide-RI drug conjugates against targets of interest to Genentech. Genentech will pay Peptidream an up-front payment of $40 million and up to $1 billion in potential development, regulatory, and commercial-based milestones. In addition, Peptidream is eligible to receive tiered royalties on net sales (ex-Japan) of any products arising from the collaboration.
RSS
